Jan-Willem Alffenaar

Jan-Willem Alffenaar is a Clinical Professor at the University of Groningen's Faculty of Medical Sciences, Department of Clinical Pharmacy and Pharmacology. His research focuses on optimizing antimicrobial therapies through pharmacokinetic/pharmacodynamic principles, particularly in critically ill patients with infectious diseases like tuberculosis (TB) and fungal infections. He emphasizes therapeutic drug monitoring, alternative sampling strategies (e.g., dried blood spots), and improving treatment outcomes through PK/PD modeling. Alffenaar collaborates internationally on studies involving anti-TB drug pharmacokinetics, clinical trials for new therapies, and global health initiatives addressing drug resistance. He contributes to clinical guidelines for adverse effect management in TB treatment and has authored over 300 peer-reviewed articles. His work aligns with UN Sustainable Development Goals related to health and well-being.

Education: Not explicitly stated in provided texts. Research and teaching activities suggest advanced training in clinical pharmacology and pharmacy.

Research Interests:

• Pharmacokinetics and pharmacodynamics of antimicrobial agents
• Optimization of antimicrobial therapy for critically ill patients
• Therapeutic drug monitoring strategies
• Alternative biospecimen sampling (e.g., dried blood spots)
• Host-directed therapies for tuberculosis
• Drug interactions in comorbid conditions (e.g., diabetes and TB)

Articles Trends: Recent work emphasizes global TB management, pediatric pharmacology, and innovative sampling techniques. Key themes include drug exposure optimization, clinical trial protocols for difficult-to-treat cases, and the impact of comorbidities on pharmacokinetics.

Labs/Teams: Associated with the Microbes in Health and Disease (MHD) research group at the UMCG. Collaborates internationally on programs like the RIAlta Trial and global TB drug quality control initiatives.